Anjali Tiku Owens, MD

Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice 

Videos

Anjali Tiku Owens, MD, shares insights into how their institution or clinic implements the Risk Evaluation and Mitigation Strategy (REMS) program for mavacamten, detailing the requirements and responsibilities of the patient in the process. Additionally, the expert draws upon their real-world experience with the cardio myosin inhibitor (CMI) in clinical practice, providing valuable perspectives on the practical application of this novel drug class.  

Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes 

Mavacamten is the first approved CMI for oHCM and is only available through the restricted Risk Evaluation and Mitigation Strategy (REMS) program. What is the purpose of this program, and how does it aim to improve medication safety and patient outcomes?

How does your institution/clinic handle the execution of the REMS program for mavacamen, how do you get certified, what are the institutional protocols?

Anjali Tiku Owens, MD, examines mavacamten, the pioneering cardio myosin inhibitor (CMI) approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), which is exclusively accessible through the restricted Risk Evaluation and Mitigation Strategy (REMS) program; the KOL delves into the objectives of this program and how it strives to enhance medication safety and optimize patient outcomes. 

Aligning With 2023 ESC Guidelines in oHCM Treatment

Where do cardiac myosin inhibitors fit into the treatment plans of your patients with oHMC, according to the most recent guidelines? 

Initiating cardiac myosin inhibitors earlier?

Use in patients who are severely symptomatic?

Anjali Tiku Owens, MD, explores the role of cardiac myosin inhibitors in the treatment strategies for patients with obstructive hypertrophic cardiomyopathy (oHCM), in accordance with the latest European Society of Cardiology (ESC) Guidelines released in 2023. 

Aligning With 2023 ESC Guidelines in oHCM Treatment 

Lessons from EXPLORER-HCM: Unveiling CMIs' Potential in oHCM Treatment  

What have we learned from clinical trials evaluating CMI’s for oHCM? 

Mavacamten: Outcomes; focused on feel and function 

Longer-term outcomes of the VALOR-HCM RCT 

Aficamten: phase 2 REDWOOD-HCM soon to be completed, phase 3 trial SEQUIOA-HCM. 

A expert cardiologist delves into the insights gained from clinical trials assessing Cardiac Myosin inhibitors (CMIs) for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), with a particular focus on the EXPLORER-HCM trial, which investigated the efficacy and safety of mavacamten in managing oHCM. 

Anjali Tiku Owens, MD

Articles